GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Price-to-Owner-Earnings

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Price-to-Owner-Earnings : (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition Price-to-Owner-Earnings?

As of today (2024-05-16), Bellevue Life Sciences Acquisition's share price is $10.76. Bellevue Life Sciences Acquisition does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Bellevue Life Sciences Acquisition's Price-to-Owner-Earnings or its related term are showing as below:


BLAC's Price-to-Owner-Earnings is not ranked *
in the Diversified Financial Services industry.
Industry Median: 8.88
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-16), Bellevue Life Sciences Acquisition's share price is $10.76. Bellevue Life Sciences Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05. Therefore, Bellevue Life Sciences Acquisition's PE Ratio for today is 215.20.

As of today (2024-05-16), Bellevue Life Sciences Acquisition's share price is $10.76. Bellevue Life Sciences Acquisition's EPS without NRI for the trailing twelve months (TTM) ended in was $0.05. Therefore, Bellevue Life Sciences Acquisition's PE Ratio without NRI for today is 215.20.

During the past 4 years, Bellevue Life Sciences Acquisition's highest PE Ratio without NRI was 693.33. The lowest was 0.00. And the median was 0.00.


Bellevue Life Sciences Acquisition Price-to-Owner-Earnings Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition Price-to-Owner-Earnings Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - -

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bellevue Life Sciences Acquisition's Price-to-Owner-Earnings

For the Shell Companies subindustry, Bellevue Life Sciences Acquisition's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellevue Life Sciences Acquisition's Price-to-Owner-Earnings Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Bellevue Life Sciences Acquisition's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Bellevue Life Sciences Acquisition's Price-to-Owner-Earnings falls into.



Bellevue Life Sciences Acquisition Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Bellevue Life Sciences Acquisition's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=10.76/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellevue Life Sciences Acquisition  (NAS:BLAC) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Bellevue Life Sciences Acquisition Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Website
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004